Cointime

Scopus BioPharma

company

About

Scopus BioPharma is a biotechnology company that focused on developing therapeutics targeting serious diseases.

  • New York,New York,United States
  • 1 - 10

Highlights

Stock Symbol
nasdaq:SCPS
Total Funding Amount
$12.16M
Funding Rounds
2
Acquisition
1
Employee Profiles
2

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$9M
Industries
Biopharma,Biotechnology,Cannabis,Medical
Founded date
Apr 1, 2018
Number Of Employee
1 - 10
Operating Status
Active
Stock Symbol
nasdaq:SCPS
Legal Name
Scopus BioPharma Inc.

Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics capitalizing on groundbreaking scientific and medical discoveries from leading research and academic institutions. The company's lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. The company is also developing additional new chemical entities to treat other serious diseases with significant unmet medical needs, including systemic sclerosis.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$12.16M
Scopus BioPharma has raised a total of $12.16M in funding over 2 rounds. Their latest funding was raised on Jan 27, 2021 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 27, 2021 Post-IPO Equity $9M — — — Detail
Dec 18, 2020 IPO $3.16M — — — Detail

Employee Profiles

Number of Employee Profiles
2
Scopus BioPharma has 2 current employee profiles, including Executive Josh Lamstein
Josh Lamstein
Executive
Morris Laster
Employee

Acquisition

Scopus BioPharma has acquired 1 organizations. Their most recent acquisition was Olimmune on Jun 30, 2021. They acquired Olimmune for 0.

Date Company Name
Industry Acquisition Type Price
Jun 30, 2021 Olimmune
Biotechnology acquisition — Detail
Cointime
Содержание
компания